

Researcher Spotlight

A Leader in Dermatology Research and Patient Care

Dr.
Fahafahantsoa
Rapelanoro
Rabenja

Dr. Fahafahantsoa Rapelanoro Rabenja at **University of Antananarivo** in Madagascar is conducting an interventional, randomized study to assess the safety and efficacy of methotrexate to treat adults in Madagascar with moderate to severe atopic dermatitis (AD). Results may improve accessibility and demonstrate effectiveness of methotrexate for Malagasy AD patients and those with darker skin globally.

Dr. Rabenja is a highly respected leader in dermatology with a track record of service. In addition to being the principal investigator of several research studies in dermatology and teledermatology, he is the President of the Malagasy Society of Dermatology, and is a past recipient of the L’Oreal African Skin and Hair Research Prize and a Certificate of Appreciation Award from The International League of Dermatological Societies. At Antananarivo University Hospital, he is the Chairman of the Board of Directors. He also currently serves as the head of the Laboratory for Research Support and Medical Informatics and Communication Technologies.

Profile

Dr. Rabenja received his MD from University of Antananarivo and studied Dermatology at Bordeaux University. He is currently the Head of University of Antananarivo’s Dermatology Department and the founder of its Medical Center and Health Digital Lab.

CWR Funding

In this trial, Dr. Rabenja and his team are studying the safety and efficacy of methotrexate in patients with atopic dermatitis. Dr. Rabenja and this study represents two of Cures Within Reach’s communities:

- Developing World / LMICs
- Health Equity



Cures Within Reach is testing already approved treatments for unsolved diseases:
driving more treatments to more patients more quickly

www.cureswithinreach.org 847.745.1252 info@cureswithinreach.org

Cures Within Reach is a 501(c)3 tax-exempt organization

